Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin

Journal of the American College of Cardiology

Volumn 33, Issue 3, 1999, Pages 796-804

  Prasad, Abhiram ^a   Husain, Syed ^a   Quyyumi, Arshed A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; NITROPRUSSIDE SODIUM;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CLINICAL ARTICLE; CORONARY ARTERY; CORONARY ARTERY DILATATION; CORONARY VASCULAR RESISTANCE; EPICARDIUM; FEMALE; HEART MUSCLE ISCHEMIA; HEART PACING; HUMAN; MALE; PRIORITY JOURNAL; SHEAR STRESS;

ADENOSINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD FLOW VELOCITY; BRADYKININ; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; ECHOCARDIOGRAPHY, DOPPLER; ENALAPRILAT; ENDOTHELIUM, VASCULAR; FEMALE; HEART CATHETERIZATION; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; NITROPRUSSIDE; PEPTIDYL-DIPEPTIDASE A; PERICARDIUM; VASODILATION; VASODILATOR AGENTS;

EID: 0033101753     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00611-1     Document Type: Article

References (46)

1. Quyyumi AA, Dakak N, Andrews NP, et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995;92:320-6.
2. Gage JE, Hess OM, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986;73:865-76.
3. Gaglione A, Hess OM, Corin WJ, et al. Is there coronary vasoconstriction after intracoronary beta-adrenergic blockade in patients with coronary artery disease? J Am Coll Cardiol 1987;10:299-310.
4. Nabel EG, Ganz P, Gordon JB, et al. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988;77:43-52.
5. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 1989;83:1946-52.
6. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
7. Vanhoutte PM. The endothelium. Modulator of vascular smooth muscle tone. N Engl J Med 1988;319:512-3.
8. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988;93:515-24.
9. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
10. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990;66:1561-75.
11. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic arteries induced by increases in heart rate. Circulation 1990;81:850-9.
12. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995;92:3424-30.
13. O'Kane KP, Webb DJ, Collier JG, Vallance PJ. Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol 1994;38:311-5.
14. Kuga T, Mohri M, Egashira K, et al. Bradykinin-induced vasodilation of human coronary in vivo: role of nitric oxide and angiotensin converting enzyme. J Am Coll Cardiol 1997;30:108-12.
15. Whalley ET, Amure YO, Lye RH. Analysis of the mechanism of action of bradykinin on human basilar artery in vitro. Naunyn Schmiedebergs Arch Pharmacol 1987;335:433-7.
16. Nakashima M, Mombouli J-V, Taylor AA, Vanhoutte PM. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993;92:2867-71.
17. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996;97:1916-23.
18. Griendling K, Ollerenshaw JD, Minieri CA, Alexander RW. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
19. Ofili E, Kern MJ, Tatineni S, et al. Detection of coronary collateral flow by a Doppler-tipped guide wire during coronary angioplasty. Am Heart J 1991;122:221-5.
20. Doucette JW, Corl D, Payne HM, et al. Validation of a doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992;85:1899-911.
21. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation. J Clin Invest 1995;95:1747-55.
22. Benjamin N, Cockcroft JR, Collier JG, et al. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol 1989;412:543-55.
23. Tousoulis D, Tentolouris C, Crake T, et al. Basal and flow-mediated nitric oxide production by atheromatous coronary arteries. J Am Coll Cardiol 1997;29:1256-62.
24. Egashira K, Katsuda Y, Mohri M, et al. Role of endothelium-derived nitric oxide in coronary vasodilation induced by pacing tachycardia in humans. Circ Res 1996;79:331-5.
25. Defily DV, Chilian WM. Coronary microcirculation: autoregulation and metabolic control. Basic Res Cardiol 1995;90:112-8.
26. Chilian WM. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation 1997;95:522-8.
27. Prasad A, Husain S, Mincemoyer R, et al. Coronary endothelial dysfunction in humans improves with angiotensin converting enzyme inhibition [abstract]. Circulation 1996;94:I-61.
28. Quyyumi AA, Dakak N, Diodati J, et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol 1997;30:1220-7.
29. El Tamimi H, Mansour M, Wargovich TJ, et al. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Endothelial function revisited. Circulation 1994;89:45-51.
30. Snow HM, McAuliffe SJ, Moors JA, Brownlie R. The relationship between blood flow and diameter in the anaesthetized dog: the role of endothelium-derived relaxing factor and shear stress. Exp Physiol 1994;79:635-45.
31. Quyyumi AA, Cannon RO, Panza JA, et al. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation 1992;86:1864-71.
32. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-22.
33. Haefeli WE, Linder L, Lüscher TF. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans. Hypertension 1997;30:912-7.
34. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-65.
35. Nakamura M, Funakoshi T, Arakawa N, et al. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with heart failure. J Am Coll Cardiol 1994;24:1321-7.
36. Prasad A, Husain S, Mincemoyer R, et al. Converting enzyme inhibition improves endothelial dysfunction in humans by increasing nitric oxide activity [abstract]. J Am Coll Cardiol 1997;29:192A.
37. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
38. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5.
39. Maggi E, Marchesi E, Ravetta V, et al. Low-density lipoprotein oxidation in essential hypertension. J Hypertens 1993;11:1103-11.
40. Ceriello A, Giugliano D, Quatraro A, et al. Metabolic control may influence the increased superoxide generation in diabetic serum. Diabetic Med 1991;8:540-2.
41. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
42. Ueda S, Elliott HL, Morton JJ, Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995;25:1266-9.
43. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/ insertion polymorphism. Circulation 1995;92:1387-8.
44. Minamino T, Kitakaze M, Matsumura Y, et al. Impact of coronary risk factors on contribution of nitric oxide and adenosine to metabolic coronary vasodilation in humans. J Am Coll Cardiol 1998;31:1274-9.
45. Schlaifer JD, Wargovich TJ, O'Neill B, et al. Effects of Quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. Am J Cardiol 1997;80:1594-7.
46. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996;27:1048-52.